Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Depreciation and Depletion (2017 - 2021)

Historic Depreciation and Depletion for Ernexa Therapeutics (ERNA) over the last 4 years, with Q1 2021 value amounting to $25163.0.

  • Ernexa Therapeutics' Depreciation and Depletion rose 940.91% to $25163.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $2.4 million, marking a year-over-year increase of 17.36%. This contributed to the annual value of $100000.0 for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q1 2021, Ernexa Therapeutics' Depreciation and Depletion is $25163.0, which was up 940.91% from $22999.0 recorded in Q1 2020.
  • In the past 5 years, Ernexa Therapeutics' Depreciation and Depletion registered a high of $2.4 million during Q4 2018, and its lowest value of $2000.0 during Q3 2018.
  • For the 4-year period, Ernexa Therapeutics' Depreciation and Depletion averaged around $558020.2, with its median value being $21999.5 (2018).
  • Over the last 5 years, Ernexa Therapeutics' Depreciation and Depletion had its largest YoY gain of 1597.63% in 2018, and its largest YoY loss of 6666.67% in 2018.
  • Over the past 4 years, Ernexa Therapeutics' Depreciation and Depletion (Quarter) stood at $2.0 million in 2017, then grew by 15.98% to $2.4 million in 2018, then tumbled by 99.02% to $22999.0 in 2020, then rose by 9.41% to $25163.0 in 2021.
  • Its last three reported values are $25163.0 in Q1 2021, $22999.0 for Q1 2020, and $2.4 million during Q4 2018.